TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Resources

Use the patient resources below to help explain TAKHZYRO to your patients and their caregivers. You'll also find TAKHZYRO information for healthcare professionals along with frequently-used forms.

FOR YOUR PATIENTS

FOR HEALTHCARE PROFESSIONALS

TAKHZYRO® patient brochure

TAKHZYRO Patient Brochure

Introduce patients to preventive treatment with TAKHZYRO using this informative brochure.1

DOWNLOAD

DESCARGAR

TAKHZYRO® Instructions for Use brochure

TAKHZYRO Instructions for Use

Walk your patients through step-by-step instructions on how to inject TAKHZYRO.

DOWNLOAD

DESCARGAR

TAKHZYRO® Next Steps brochure

TAKHZYRO Next Steps Brochure

Use this digital brochure to help patients understand the onboarding process after being prescribed TAKHZYRO.

DOWNLOAD

TAKHZYRO® Adherence brochure

TAKHZYRO Adherence Brochure

Learn how you can get the most out of your treatment by taking TAKHZYRO exactly as your doctor has prescribed it.

DOWNLOAD

Prescribing Information for TAKHZYRO®

Prescribing Information

Provide the full Prescribing Information for TAKHZYRO to new patients.

DOWNLOAD

DESCARGAR

Encourage patient education

Lexi, a real TAKHZYRO® patient

Your patients might benefit from seeing how other people are reimagining their lives with TAKHZYRO. Encourage them to explore our video gallery.

Patients can watch here

Smartphone and texting bubble images - TAKHZYRO® patients can sign up for dosing reminders

Some of your patients may need help remembering to take TAKHZYRO as you've prescribed. Encourage them to sign up for dosing reminders.

Patients can sign up here

HAEA: US Hereditary Angioedema Association logo

Your HAE patients can continue to explore resources and connect with support offered through the US Hereditary Angioedema Association (HAEA).

VISIT HAEA.ORG

View a real patient case from the perspective of the treating HCP

Jason, a real TAKHZYRO® patient

Jason started TAKHZYRO after only
being treated with acute therapy.

DOWNLOAD

Lisa, a real TAKHZYRO® patient

Lisa is a TAKHZYRO patient with previous prophylactic use.

DOWNLOAD

Review information about TAKHZYRO

TAKHZYRO® Clinical Studies brochure

TAKHZYRO Clinical Studies Brochure

Learn about one of the largest prevention studies in HAE with the longest active treatment duration.

DOWNLOAD

TAKHZYRO® brochure

TAKHZYRO Brochure

Review and learn more about the efficacy, dosing/administration and safety of TAKHZYRO.

DOWNLOAD

Find helpful forms and information for your practice

TAKHZYRO® Start Form

TAKHZYRO Start Form

Download the OnePath® Start Form and fill it out to get your patients started on TAKHZYRO.

DOWNLOAD

TAKHZYRO® Office Resource Kit Annotated Start Form

TAKHZYRO Office Resource Kit Annotated Start Form

Use this sample Start Form as a guide when completing a TAKHZYRO Start Form.

DOWNLOAD

TAKHZYRO® Quick Start Form

TAKHZYRO Quick Start Form

Fill this form out to enroll your patients in the TAKHZYRO Quick Start Program.

DOWNLOAD

TAKHZYRO® Office Resource Kit Checklist

TAKHZYRO Office Resource Kit Checklist

Use this checklist to ensure you have the necessary documentation and information needed for your TAKHZYRO patients.

DOWNLOAD

TAKHZYRO® Office Resource Kit One Pager Matrix

TAKHZYRO Office Resource Kit One Pager Matrix

Keep contact information for your TAKHZYRO patients’ Takeda team on hand.

DOWNLOAD

Find additional documents sometimes requested by insurance companies

Statement of Medical Necessity for TAKHZYRO®

Statement of Medical Necessity

DOWNLOAD

Letter of Intent to treat with TAKHZYRO®

Letter of Intent to Treat

DOWNLOAD

Coverage Denial letter

Coverage Denial Letter

DOWNLOAD

Formulary Exception Letter

Formulary Exception Letter

DOWNLOAD

Claim Denial Letter

Claim Denial Letter

DOWNLOAD

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-FDA-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-FDA-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

Reference: 1. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Dyax Corp 2018.